Gilead Sciences (GILD) Receivables - Net (2009 - 2026)

Gilead Sciences (GILD) has reported Receivables - Net for 18 consecutive years, with $4.7 billion the latest figure, recorded in Q1 2026.

• Receivables - Net for Q1 2026 came in at $4.7 billion, up 8.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 billion (up 8.04% YoY), and the FY2025 annual result was $5.9 billion, up 33.37% from the prior year.
• Receivables - Net was $4.7 billion for Q1 2026 at Gilead Sciences, down from $5.9 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $5.9 billion in Q4 2025 and troughed at $3.8 billion in Q1 2022.
• Average Receivables - Net over 5 years is $4.7 billion, with a median of $4.7 billion recorded in 2024.
• Year-over-year, Receivables - Net fell 19.56% in 2024 and surged 33.37% in 2025.
• Over 5 years, Receivables - Net stood at $5.5 billion in 2022, then climbed by 0.57% to $5.5 billion in 2023, then retreated by 19.56% to $4.4 billion in 2024, then soared by 33.37% to $5.9 billion in 2025, then declined by 19.58% to $4.7 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $4.7 billion in Q1 2026, $5.9 billion in Q4 2025, and $5.1 billion in Q3 2025.